The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Progestin-only contraception and thromboembolism: A systematic review
Open accessAbstract
Background: Women with medical conditions associated with increased risk for thrombosis generally should not use estrogen-containing contraceptives; however, less is known about progestin-only contraceptives (POCs) and thrombosis risk. Objectives: The objective was to identify evidence regarding the risk of venous thromboembolism (VTE) or arterial thromboembolism [stroke or acute myocardial infarction (AMI)] among women using POCs. Methods: We searched the PubMed database for all articles published from database inception through January 2016 for studies examining thrombosis among women using POCs. We included studies which examined women with medical conditions associated with thrombosis risk, as well as studies of women in the general population (either without these conditions or who were not specified to have these conditions). Hormonal contraceptives of interest included progestin-only pills (POPs), injectables, implants and levonorgestrel-releasing intrauterine devices (LNG-IUDs). Outcomes of interest included VTE, stroke and AMI. Results: There were 26 articles of good to poor quality that met inclusion criteria; 9 studies examined women with medical conditions and 20 examined women in the general population. Two studies found that, among smokers and women with certain thrombogenic mutations, use of depot medroxyprogesterone acetate (DMPA) had elevated odds of VTE compared with nonsmokers or those without mutations, although confidence intervals were wide and overlapped with odds among nonusers. One study found that, among women with previous VTE, use of POCs (including DMPA) was associated with a nonsignificant increased odds of recurrent VTE (all of which were among DMPA users); two other studies that examined POCs other than DMPA did not observe an association with recurrent VTE. Two studies found that use of DMPA among healthy women was also associated with increased odds of VTE. Two studies found that use of POCs for therapeutic indications was associated with increased odds of VTE. Studies did not find increased odds of VTE with POPs for contraceptive purposes, implants or LNG-IUDs nor were there increased odds of stroke or AMI with any POCs. Conclusion: The majority of evidence identified by this systematic review did not suggest an increase in odds for venous or arterial events with use of most POCs. Limited evidence suggested increased odds of VTE with use of injectables (three studies) and use of POCs for therapeutic indications (two studies, one with POCs unspecified and the other with POPs). Any increase in risk likely translates to a small increase in absolute numbers of thrombotic events at the population level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Current methods of the U.S. Preventive Services Task Force
Harris, R. P., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,731
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
Self-citationCardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis
Ageno, W., Becattini, C., Brighton, T., Selby, R., & Kamphuisen, P. W. (2008) · Circulation · doi:10.1161/circulationaha.107.709204 · Cited by 974
Jick, H., Jick, S. S., Myers, M. W., Vasilakis, C., & Gurewich, V (1995) · The Lancet · doi:10.1016/s0140-6736(95)91928-7 · Cited by 726
Hormonal contraception and risk of venous thromboembolism: national follow-up study
Lidegaard, O., Lokkegaard, E., Svendsen, A. L., & Agger, C. (2009) · BMJ · doi:10.1136/bmj.b2890 · Cited by 709
van Hylckama Vlieg, A., Helmerhorst, F. M., Vandenbroucke, J. P., Doggen, C. J. M., & Rosendaal, F. R. (2009) · BMJ · doi:10.1136/bmj.b2921 · Cited by 666
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
Thrombotic stroke and myocardial infarction with hormonal contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111840 · Cited by 607
Spitzer, W. O., Lewis, M. A., Heinemann, L. A. J., Thorogood, M., & MacRae, K. D. (1996) · BMJ · doi:10.1136/bmj.312.7023.83 · Cited by 594
Case-control study of migraine and risk of ischaemic stroke in young women
Tzourio, C., Tehindrazanarivelo, A., Iglesias, S., Alperovitch, A., Chedru, F., d'Anglejan-Chatillon, J., & Bousser, M.-G. (1995) · BMJ · doi:10.1136/bmj.310.6983.830 · Cited by 511
Stegeman, B. H., de Bastos, M., Rosendaal, F. R., van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2013) · BMJ · doi:10.1136/bmj.f5298 · Cited by 420
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003216 · Cited by 367
Oral contraceptives and venous thromboembolism: a five-year national case-control study☆
Lidegaard, Ø., Edström, B., & Kreiner, S. (2002) · Contraception · doi:10.1016/s0010-7824(01)00307-9 · Cited by 334
Stroke in Users of Low-Dose Oral Contraceptives
Petitti, D. B., Sidney, S., Bernstein, A., Wolf, S., Quesenberry, C., & Ziel, H. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350102 · Cited by 329
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2012) · BMJ · doi:10.1136/bmj.e2990 · Cited by 326
Thrombotic Stroke and Myocardial Infarction With Hormonal Contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000422965.64164.ac · Cited by 292
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
Curtis, K. M., Tepper, N. K., & Marchbanks, P. A. (2011) · Journal of Women's Health · doi:10.1089/jwh.2011.2851 · Cited by 261
Self-citation(1998) · Contraception · doi:10.1016/s0010-7824(98)00041-9 · Cited by 259
Mantha, S., Karp, R., Raghavan, V., Terrin, N., Bauer, K. A., & Zwicker, J. I. (2012) · BMJ · doi:10.1136/bmj.e4944 · Cited by 258
Mechanisms of estrogen-induced venous thromboembolism
Tchaikovski, S. N., & Rosing, J. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.01.045 · Cited by 219
Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
Lidegaard, O. (1993) · BMJ · doi:10.1136/bmj.306.6883.956 · Cited by 216
Risk factors for venous thrombosis – current understanding from an epidemiological point of view
Lijfering, W. M., Rosendaal, F. R., & Cannegieter, S. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08206.x · Cited by 214
U S. Medical Eligibility Criteria for Contraceptive Use, 2010.
(2010) · PubMed · Cited by 202
Risk of idiopathic venous thromboembolism in users of progestagens alone
Vasilakis, C., Jick, H., & del Mar Melero-Montes, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04394-9 · Cited by 189
Oral contraceptives and venous thromboembolism
Lidegaard, Ø., Edström, B., & Kreiner, S. (1998) · Contraception · doi:10.1016/s0010-7824(98)00033-x · Cited by 186
van Hylckama Vlieg, A., Helmerhorst, F. M., & Rosendaal, F. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.211482 · Cited by 175
Dunn, N., Thorogood, M., Faragher, B., de Caestecker, L., MacDonald, T. M., McCollum, C., Thomas, S., Mann, R., & Lidegaard, O. (1999) · BMJ · doi:10.1136/bmj.318.7198.1579 · Cited by 169
Risk of Venous Thromboembolism During the Postpartum Period
Jackson, E., Curtis, K. M., & Gaffield, M. E. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31820ce2db · Cited by 148
Self-citationRisk of Acute Thromboembolic Events With Oral Contraceptive Use
Urrutia, R. P., Coeytaux, R. R., McBroom, A. J., Gierisch, J. M., Havrilesky, L. J., Moorman, P. G., Lowery, W. J., Dinan, M. A., Hasselblad, V., Sanders, G. D., et al. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3182994c43 · Cited by 147
Poulter, N. R., Cl, C., Farley, T., Marmot, M. G., & Meirik, O. (1998) · PubMed · Cited by 140
Progestogen-only contraception in women at high risk of venous thromboembolism
Conard, J., Plu‐Bureau, G., Bahi, N., Horellou, M., Pelissier, C., & Thalabard, J. (2004) · Contraception · doi:10.1016/j.contraception.2004.07.009 · Cited by 137
Contraceptives and cerebral thrombosis: a five-year national case-control study☆
Lidegaard, Ø., & Kreiner, S. (2002) · Contraception · doi:10.1016/s0010-7824(01)00306-7 · Cited by 134
Heinemann, L. A. J., Assmann, A., DoMinh, T., & Garbe, E. (1999) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189909064007 · Cited by 126
Use of Low-Dose Oral Contraceptives and Stroke in Young Women
Schwartz, S. M., Siscovick, D. S., Longstreth, W. T., Jr., Psaty, B. M., Beverly, R. K., Raghunathan, T. E., Lin, D., & Koepsell, T. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_1-199710150-00003 · Cited by 111
Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event
Christiansen, S. C., Lijfering, W. M., Helmerhorst, F. M., Rosendaal, F. R., & Cannegieter, S. C. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03994.x · Cited by 108
Low-Dose Oral Contraceptive Use and the Risk of Myocardial Infarction
Rosenberg, L. A., Palmer, J. R., Rao, S. R., & Shapiro, S. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.8.1065 · Cited by 103
Progestogen-Only Contraceptives and the Risk of Stroke
Chakhtoura, Z., Canonico, M., Gompel, A., Thalabard, J., Scarabin, P., & Plu‐Bureau, G. (2009) · Stroke · doi:10.1161/strokeaha.108.538405 · Cited by 102
Roach, R. E. J., Lijfering, W. M., Helmerhorst, F. M., Cannegieter, S. C., Rosendaal, F. R., & Vlieg, A. V. H. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12060 · Cited by 99
Barsoum, M. K., Heit, J. A., Ashrani, A. A., Leibson, C. L., Petterson, T. M., & Bailey, K. R. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.08.010 · Cited by 98
Effects of progestogens on haemostasis
Kühl, H. (1996) · Maturitas · doi:10.1016/0378-5122(96)00994-2 · Cited by 95
Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes
Bergendal, A., Persson, I., Odeberg, J., Sundström, A., Holmström, M., Schulman, S., Björgell, O., & Kieler, H. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000411 · Cited by 93
Poulter, N. R., Chang, C., Farley, T., & Meirik, O. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03132-3 · Cited by 87
Myocardial infarction in users of low-dose oral contraceptives
Sidney, S., Bpetitti, D., PQUESENBERRYJR, C., LKlatsky, A., KZIEL, H., & WOLF, S. (1996) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(96)00351-1 · Cited by 87
Thorogood, M., Mann, J. I., Murphy, M. F. G., & Vessey, M. P. (1991) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1991.tb15397.x · Cited by 75
Progestogen-Only Contraceptives and the Risk of Acute Myocardial Infarction: A Meta-Analysis
Chakhtoura, Z., Canonico, M., Gompel, A., Scarabin, P., & Plu‐Bureau, G. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2065 · Cited by 74
Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives
Alhenc‐Gelas, M., Plu‐Bureau, G., Guillonneau, S., Kirzin, J.-M., Aiach, M., Ochat, N., & Scarabin, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00894.x · Cited by 72
A multinational case-control study of cardiovascular disease and steroid hormone contraceptives
Debert-Ribeiro, M., Medina, E., Artigas, J., He, S., Hui, Z. Y., Zhang, D. W., Rojas, O., Vessey, M., Heinemann, L., Donnan, S., et al. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00516-1 · Cited by 56
Progestin-only contraception and venous thromboembolism
Blanco-Molina, M. Á., Lozano, M., Cano, A., García, I. C., Pallardó, L., & Lete, I. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.02.042 · Cited by 52
Vieira, C. S., Ferriani, R. A., Garcia, A. A., Pintão, M. C. T., Azevedo, G. D., Gomes, M. K. O., & Silva-de-Sa, M. F. (2007) · Human Reproduction · doi:10.1093/humrep/dem153 · Cited by 48
Limited knowledge on progestogen‐only contraception and risk of venous thromboembolism
Bergendal, A., Odlind, V., Persson, I. R., & Kieler, H. (2009) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340902730375 · Cited by 48
Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives
Vaillant-Roussel, H., Ouchchane, L., Dauphin, C., Philippe, P., & Ruivard, M. (2011) · Contraception · doi:10.1016/j.contraception.2011.06.008 · Cited by 43
Risk factors for venous thromboembolism in pre-and postmenopausal women
Bergendal, A., Bremme, K. A., Hedenmalm, K., Lärfars, G., Odeberg, J., Persson, I. R., Sundström, A., & Kieler, H. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.05.024 · Cited by 43
Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study
Moigne, E. L., Tromeur, C., Delluc, A., Gouillou, M., Alavi, Z., Lacut, K., Mottier, D., & Gal, G. L. (2015) · Haematologica · doi:10.3324/haematol.2015.134882 · Cited by 41
Contraception with progestagens in systemic lupus erythematosus
Mintz, G., GUTIERREZ, G., Delezé, M., & Rodríguez, E. (1984) · Contraception · doi:10.1016/0010-7824(84)90076-3 · Cited by 39
Norplant® implants and cardiovascular disease
Petitti, D. B., Siscovick, D., Sidney, S., et al. (1998) · Contraception · doi:10.1016/s0010-7824(98)00036-5 · Cited by 21
Cited by
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
Self-citationOkoth, K., Chandan, J. S., Marshall, T., Thangaratinam, S., Thomas, G. N., Nirantharakumar, K., & Adderley, N. J. (2020) · BMJ · doi:10.1136/bmj.m3502 · Cited by 416
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Contraception Selection, Effectiveness, and Adverse Effects: A Review
Teal, S., & Edelman, A. (2021) · JAMA · doi:10.1001/jama.2021.21392 · Cited by 336
(2019) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003072 · Cited by 147
Metadata
- Authors
- Tepper, N. K., Whiteman, M. K., Marchbanks, P. A., James, A. H., & Curtis, K. M.
- Venue
- Contraception
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 94
- Issue
- 6
- Pages
- 678-700
- ISSN
- 0010-7824 (ISSN-L)
- OpenAlex
- W2346324895
- Cited by
- 272
- References
- 57
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.